Raltegravir News and Research

RSS
Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Novel integrase inhibitor dolutegravir shows promise for HIV-1 treatment

Novel integrase inhibitor dolutegravir shows promise for HIV-1 treatment

All adult patients with HIV should be offered ART: International Antiviral Society-USA panel

All adult patients with HIV should be offered ART: International Antiviral Society-USA panel

AIDS battle: stretching use of anti-HIV drugs

AIDS battle: stretching use of anti-HIV drugs

Once-daily pill for HIV is a safe and effective alternative to traditional antiretroviral regimens

Once-daily pill for HIV is a safe and effective alternative to traditional antiretroviral regimens

Gilead submits elvitegravir NDA with FDA for treatment of HIV-1 infection

Gilead submits elvitegravir NDA with FDA for treatment of HIV-1 infection

Gilead's elvitegravir MAA for HIV-1 infection receives EMA validation

Gilead's elvitegravir MAA for HIV-1 infection receives EMA validation

ViiV, Shionogi announce initial results from dolutegravir Phase III study on HIV-1

ViiV, Shionogi announce initial results from dolutegravir Phase III study on HIV-1

FDA approval of raltegravir offers new weapon to treat HIV infection in children

FDA approval of raltegravir offers new weapon to treat HIV infection in children

FDA approves Merck's Isentress to treat HIV-1 infection in children, adolescents

FDA approves Merck's Isentress to treat HIV-1 infection in children, adolescents

ACTF, Merck announce new HIV initiatives

ACTF, Merck announce new HIV initiatives

Merck third quarter global sales increase 8% to $12.0 billion

Merck third quarter global sales increase 8% to $12.0 billion

Merck announces results from ISENTRESS Phase III combination study on HIV-1

Merck announces results from ISENTRESS Phase III combination study on HIV-1

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Merck reports worldwide sales of $12.2 billion for second quarter 2011

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

Merck first quarter sales increase 1% to $11.6 billion for 2011

Merck first quarter sales increase 1% to $11.6 billion for 2011

Gilead's elvitegravir Phase III trial against HIV-1 meets primary objective

Gilead's elvitegravir Phase III trial against HIV-1 meets primary objective

Merck reports GAAP net income of $861 million for 2010

Merck reports GAAP net income of $861 million for 2010

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Merck announces initial results from ISENTRESS Phase III study in HIV-1

ORVACS launches ERAMUNE 01 Phase II study to decrease HIV viral reservoirs

ORVACS launches ERAMUNE 01 Phase II study to decrease HIV viral reservoirs